Clinical Trial Update: An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia [Phase 3]

View source ↗

Summary

Open-label Phase 3 study of KarXT in schizophrenia was terminated; results were posted on 2024-06-12.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2024-06-12